HighTide Therapeutics (HKSE:02511) Price-to-Free-Cash-Flow : N/A (As of Jun. 06, 2024)

View and export this data going back to 2023. Start your Free Trial

What is HighTide Therapeutics Price-to-Free-Cash-Flow?

As of today (2024-06-06), HighTide Therapeutics's share price is HK$4.50. HighTide Therapeutics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-0.76. Hence, HighTide Therapeutics's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for HighTide Therapeutics's Price-to-Free-Cash-Flow or its related term are showing as below:

HKSE:02511's Price-to-Free-Cash-Flow is not ranked ^*
in the Biotechnology industry.
Industry Median: 30.425
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

HighTide Therapeutics's Free Cash Flow per Share for the six months ended in Dec. 2023 was HK$-0.46. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was HK$-0.76.

HighTide Therapeutics Price-to-Free-Cash-Flow Historical Data

The historical data trend for HighTide Therapeutics's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HighTide Therapeutics Price-to-Free-Cash-Flow Chart

HighTide Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Price-to-Free-Cash-Flow

HighTide Therapeutics Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23
Price-to-Free-Cash-Flow	-	-	-	-	-

Competitive Comparison of HighTide Therapeutics's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, HighTide Therapeutics's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

HighTide Therapeutics's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, HighTide Therapeutics's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where HighTide Therapeutics's Price-to-Free-Cash-Flow falls into.

HighTide Therapeutics Price-to-Free-Cash-Flow Calculation

HighTide Therapeutics's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio	=	Share Price	/	Free Cash Flow per Share (TTM)
	=	4.50	/	-0.762
	=	N/A

HighTide Therapeutics's Share Price of today is HK$4.50.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. HighTide Therapeutics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-0.76.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio

Market Cap

Free Cash Flow

HighTide Therapeutics (HKSE:02511) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.

Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.

HighTide Therapeutics Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of HighTide Therapeutics's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

HighTide Therapeutics (HKSE:02511) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HighTide Therapeutics Inc (HKSE:02511) » Definitions » Price-to-Free-Cash-Flow

Comparable Companies

Traded in Other Exchanges

N/A

Address

Ganli Second Road, 18B-102, Zhonghaixin Innovation Industry City, Jihua Neighborhood, Longgang District, Guangdong, Shenzhen, CHN, 518112

Website

https://www.hightidetx.com

HighTide Therapeutics Inc is a biopharmaceutical company specializing in the discovery, development and commercialization of multifunctional, multi-targeted therapies for the treatment of metabolic and digestive diseases. The company has developed a product pipeline of five product candidates in-house, covering nine indications in metabolic and digestive diseases among which, five are at clinical-stage. The Core Product, HTD1801 (berberine ursodeoxycholate), a new molecular entity, is a gut-liver anti-inflammatory metabolic modulator which targets multiple pathways pivotal to metabolic regulation, including those associated with metabolic and digestive diseases.

Executives

Ma Lixiong	2101 Beneficial owner
Liu Liping	2101 Beneficial owner
Li Li	2201 Interest of corporation controlled by you
The Core Trust Company Limited
Shan Miao	2201 Interest of corporation controlled by you
Medi Prosperity Capital Inc.	2201 Interest of corporation controlled by you
Hepalink Healthcare Partners I L.p	2201 Interest of corporation controlled by you
Hepalink Biotechnology Ii Limited	2101 Beneficial owner
Hepalink (hong Kong) Limited	2201 Interest of corporation controlled by you
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.	2501 Other
Wisdom Spring Group Limited
Tct (bvi) Limited
Baiyi Capital Limited	2101 Beneficial owner
Lai Hoi Man	2201 Interest of corporation controlled by you
Hongtu Capital Limited	2101 Beneficial owner

HighTide Therapeutics (HKSE:02511) Headlines

No Headlines